Pfizer monitors new hemophilia drug for safety
NCT ID NCT07161687
Summary
This study is checking the safety of a drug called Hympavzi in real-world use by patients with hemophilia A or B. It will follow about 50 patients for up to three years to see if any unexpected side effects occur. The main goal is to understand the drug's safety profile after it has been made available to the public.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A OR B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer, Inc
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.